Alveltamig
AbbVie Partners with China’s Zelgen on DLL3-Targeted T-Cell Engager ZG006 in Up-to-$1.2B Deal
AbbVie; Zelgen; ZG006; Alveltamig; DLL3; T-cell engager; small cell lung cancer; licensing deal
Actionable Insights Powered by AI
AbbVie; Zelgen; ZG006; Alveltamig; DLL3; T-cell engager; small cell lung cancer; licensing deal